LRRK2 Nuclease
Parkinson's Disease
Pre-clinicalActive
Key Facts
About Neoclease
Neoclease is an early-stage biotech leveraging a proprietary generative AI platform to engineer novel, custom nucleases for therapeutic gene editing. The company's core technology combines synthetic biology with AI trained on known nuclease data to design enzymes with high specificity and efficacy, particularly for targets in tissues traditionally inaccessible to CRISPR. With a lead program targeting Parkinson's disease and a platform approach to over 6,000 monogenic diseases, Neoclease is positioning itself at the intersection of AI and next-generation genetic medicine. The company is privately held, pre-revenue, and in the pre-clinical stage of development.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ABBV-951 | AbbVie | Phase 3 |
| UCB0107 | UCB | Phase 1 |
| Stalevo | Orion Corporation | Approved |
| Comtan/Comtess | Orion Corporation | Approved |
| NPT200-11 | Neuropore Therapies | Phase 1 |
| CHRONOS-PD Platform | Grifols | Research |
| GT-001 (Gene Therapy) | Sumitomo Pharma | Phase 1/2 |
| CREXONT (Carbidopa/Levodopa) | Amneal Pharmaceuticals | Approved |
| BIIB122/DNL151 | Denali Therapeutics | Phase 3 |
| ABBV-0805 | BioArctic AB | Phase 1 |
| BAN1202 | BioArctic AB | Preclinical |
| ARV-102 | Arvinas | Phase 1 |